[OncoHost in Startup News] Clinical Lung Cancer publishes study: 93% of Oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC™ test

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC™ test on first-line treatment decisions for metastatic non-small cell lung cancer (NSCLC) patients.